Alkermes plc LogoGraphic Source: Alkermes plc

Introduction: What is Alkermes plc?

Alkermes plc (ALKS) is a global biopharmaceutical company focused on developing and commercializing products related to schizophrenia, Bipolar I Disorder, Opioid/Alcohol Dependence, and recently Oncology. They are focused on unmet medical needs in major therapeutic areas and retain a diversified portfolio of approved revenue-producing therapeutics and a promising pipeline.

Since its founding in 1987, Alkermes has since grown to over 2,235 employees with revenues of $1.17B and a market cap of $2.68B. Alkermes is headquartered in Ireland with mix-purpose facilities (R&D and manufacturing) also in the USA.

Products: Alkermes has three marketed products, two licensed products, and a few other technology leases that all bring in sustainable revenue of varying levels. Their first product was ARISTADA (aripiprazole lauroxil), a 6w-2m dosing extended-release intramuscular injectable approved in the U.S. for the treatment of schizophrenia. ARISTADA rolled out an add-on, ARISTADA INITIO, which is an extended-release formulation of aripiprazole lauroxil with a smaller particle size thus faster dissolution and more rapid achievement of relevant levels of aripiprazole in the body. It is used as an initiation supplement for ARISTADA. Their third product is VIVITROL (naltrexone for extended-release injectable suspension), a once-monthly non-narcotic, injectable medication approved in the U.S., Russia, and certain CIS countries for the treatment of alcohol and opioid dependence. Alkermes licenses other products and technology for royalty/licensing fees.

Customers/market: Alkermes operates primarily for patients being treated for 1) schizophrenia, 2) alcohol dependence, 3) Opioid dependence, 4) Bipolar I Disorder, 5) Multiple Sclerosis, and 6) Oncology.

Management: Planned 2021 changes regarding consolidating the three-classes of directors into one and reducing term length from 3-year to 1-year for board members are key changes that should create a more youthful, independent and innovative board. In terms of key management, please see below:

Chairman/CEO: Richard